Design studies of nebulization in COPD does not respond adequately to the clinically relevant question: the intervention of administering nebulized bronchodilators at home it is likely to make a profit, compared to the standard optimized treatment as defined by the recommendations of the SPLF, patients with severe COPD (stage III, FEV between 30% and 50% of the theoretical value) and very severe (stage IV, less than 30% of the theoretical value FEV)? The concept of profit in this context is based on criteria of dyspnea, quality of life, use of health system (exacerbations, hospitalizations, prescription of antibiotics and steroids ...).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
SINGLE
Enrollment
45
3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
1 capsule lactose during 48 weeks
Service de Pneumologie
Amiens, France
Service de Pneumologie
Angers, France
Service de Pneumologie
Brest, France
Service de Pneumologie
Grenoble, France
Service de Pneumologie
Limoges, France
Service de Pneumologie
Nancy, France
Service de Pneumologie
Nantes, France
Service de Pneumologie
Orléans, France
Service de Pneumologie
Paris, France
Service de Pneumologie
Poitiers, France
...and 3 more locations
Score for quality of life, assessed by the questionnaire St Georges
Time frame: Patients will be followed for the duration of their participation ie 48 weeks
Score for quality of life, assessed by the questionnaire VQ11
Time frame: Patients will be followed for the duration of their participation ie 48 weeks
Dyspnea score according Medical Research Council
Time frame: Patients will be followed for the duration of their participation ie 48 weeks
Prognostic Score Mortality assessed by the score BODE
Time frame: Patients will be followed for the duration of their participation ie 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.